Functional Mimicry of an Anti‐idiotypic Antibody to Nominal Antigen on Cellular Response

Ma, Jie; Zhou, Libing; Wang, Daqing

doi:10.1111/j.1349-7006.2002.tb01203.x

Cited by 12 publications

(8 citation statements)

References 23 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides this, anti-ID antibodies induce a memory response (through the generation of T-helper memory cells) that not only persists following treatment but also prevents the occurrences of relapses [ 48 ] and promotes longer-lasting immunity [ 49 ]. In addition, since anti-ID antibodies naturally occur in the body [ 56 ] and the immune response elicited mimics those induced by nominal antigen [ 57 ], they are fairly safe and should not cause toxicity [ 58 ]. Vaccination with Ab2 has shown various advantages, as they bear the internal image of the antigen [ 59 ].…”

Section: Anti-id Antibodies For Immunotherapy and Their Advantagesmentioning

confidence: 99%

Immunomodulatory Potential of anti-idiotypic Antibodies for the Treatment of Autoimmune Diseases

Pan¹,

Chia²,

Yee³

et al. 2020

Future Sci. OA

View full text Add to dashboard Cite

The immune system is a complex network of specialized cells and organs that recognises and reacts against foreign pathogens while remaining unresponsive to host tissues. This ability to self-tolerate is known as immunological tolerance. Autoimmune disease occurs when the immune system fails to differentiate between self and non-self antigens and releases autoantibodies to attack our own cells. Anti-idiotypic (anti-ID) antibodies are important in maintaining a balanced idiotypic regulatory network by neutralising and inhibiting the secretion of autoantibodies. Recently, anti-ID antibodies have been advanced as an alternative form of immunotherapy as they can specifically target autoantibodies, cause less toxicity and side effects, and could provide long-lasting immunity. This review article discusses the immunomodulatory potential of anti-ID antibodies for the treatment of autoimmune diseases.

show abstract

Section: Anti-id Antibodies For Immunotherapy and Their Advantagesmentioning

confidence: 99%

Immunomodulatory Potential of anti-idiotypic Antibodies for the Treatment of Autoimmune Diseases

Pan¹,

Chia²,

Yee³

et al. 2020

Future Sci. OA

View full text Add to dashboard Cite

show abstract

“…13 In order to determine whether the CA19.9-LC44 immunocomplex could trigger antigen-specific cytotoxicity, a 4-hour 51 Cr release assay was performed. As depicted in Figure 4, CA19.9-positive tumor cells (SW1116) were lysed by antigen-and/or antibody-primed T-cells, while CA19.9-negative tumor targets (Lo Vo) were hardly affected.…”

Section: Immunocomplex Could Stimulate Ctl Productionmentioning

confidence: 99%

Antitumor Effect of an Antibody Against Gastrointestinal Cancer–Associated Antigen CA19.9

Liu

Wan³

et al. 2007

Cancer Biotherapy and Radiopharmaceuticals

Self Cite

View full text Add to dashboard Cite

Despite tremendous efforts in developing cancer vaccines and monoclonal antibodies (mAbs), only a few passive or active immunotherapeutic modalities have succeeded. The failure may be due to the existence of immunosuppressive factors, which caused anergy of patients' immune system. In this study, we discovered that CA19.9 is one such immunosuppressive factor, which could inhibit the proliferation of activated human lymphocytes. However, this inhibition could be reversed by a mAb, LC44, which was specifically generated against CA19.9. An in vitro cytotoxic experiment showed that mAb LC44 could form an immunocomplex with CA19.9, which subsequently induced the production of cytotoxic T-cells reacting to CA19.9-positive cancer cells. In addition, mAb LC44 could mediate the complement-dependent cytotoxicity to CA19.9-positive cancer cells. mAb LC44 showed an antitumor effect in immunodeficient mice with colon cancer burden in the presence or absence of CA19.9. Based on the observations from this study, we postulated that the mAb, LC44, could be a promising antitumor agent for gastrointestinal cancer and worthy of further investigation.

show abstract

“…Consequently, with this approach, there is no use of external Ag or its fragments in Id-based vaccines. The Id vaccines production may reduce the likelihood of unwanted side effects which are mostly associated with typical Ag vaccines [49]. Anti-Id vaccines provoke a higher immune response of fine specificities than for antigen vaccines.…”

Section: Choice Of Anti-idiotype As Vaccine Candidatementioning

confidence: 99%

Recapitulation of the anti-Idiotype antibodies as vaccine candidate

et al. 2018

View full text Add to dashboard Cite

The foreign antigen that enters into the body is detected by the immune system through antigen presenting cells leading to the production of antibodies. The use of anti-idiotype antibodies is a new way to excite the immune response that identifies and eliminates the foreign antigens entered into the body. These Anti-idiotype antibodies have the ability to decrease the non-specific binding of the antigenic protein epitopes because of high specificity for the antigenic determinants. The anti-idiotype antibodies attach to the paratope of idiotype antibody and stimulate a precise immune reaction same as that of external antigen. The anti-idiotype antibodies are the peerless therapeutic candidate as they mimic the antigenic structure and potentiate antibody and cell-mediated immunity. Even in the absence of foreign antigen, these anti-idiotype antibodies have the potential to provide long-lasting immunity. The present review is about immune regulations by anti-idiotype antibodies with some success therapeutic stories. The previous research analysis is evidence of anti-idiotype antibodies as an excellent candidate for the development of both human and animal vaccines although it has some gaps that are needed to be addressed.

show abstract

Functional Mimicry of an Anti‐idiotypic Antibody to Nominal Antigen on Cellular Response

Cited by 12 publications

References 23 publications

Immunomodulatory Potential of anti-idiotypic Antibodies for the Treatment of Autoimmune Diseases

Immunomodulatory Potential of anti-idiotypic Antibodies for the Treatment of Autoimmune Diseases

Antitumor Effect of an Antibody Against Gastrointestinal Cancer–Associated Antigen CA19.9

Recapitulation of the anti-Idiotype antibodies as vaccine candidate

Contact Info

Product

Resources

About